Medtronic Reports Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Strong AI earnings lift S&P 500, Nasdaq as inflation data calms rate-hike jitters
- Oil prices little changed as investors weigh lower demand against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Medtronic, Inc. (MDT) PT Raised to $87 at Oppenheimer Following 3Q Report
February 22, 2017 9:23 AM ESTOppenheimer raised its price target on Medtronic, Inc. (NYSE: MDT) to $87.00 (from $84.00) while maintaining a Outperform rating.
Analyst Steven Lichtman commented, "MDT's F3Q sales (+6% cc) came in ahead, with each major segment coming in slightly above our thinking, and growth evenly split... More
Wedbush Maintains Neutral Rating and $85 PT on Medtronic (MDT) Following F3Q17 Results
February 22, 2017 7:52 AM ESTWedbush Securities analyst Tao Levy reiterates Neutral rating and $85 price target on Medtronic Plc (NYSE: MDT), suggesting solid results demonstrate recovery from last quarters disruptions, as the company reported fiscal 2017 third quarter revenues above consensus estimates.
Levy comments, "Medtronics broad product portfolio allows the company to... More
Medtronic, Inc. (MDT) PT Raised to $91 at Needham & Company
February 21, 2017 1:38 PM ESTNeedham & Company raised its price target on Medtronic, Inc. (NYSE: MDT) to $91.00 (from $84.00) while maintaining a Buy rating. 3Q revenue was $7.283B vs. consensus estimates of $7.221B and adjusted EPS was $1.12 vs. consensus of $1.11.
Analyst Mike Matson commented, "F3Q17 revenue and... More
Medtronic, Inc. (MDT) PT Raised to $88 at Evercore ISI
February 21, 2017 11:50 AM ESTEvercore ISI raised its price target on Medtronic, Inc. (NYSE: MDT) to $88.00 (from $78.00) while maintaining a Buy rating following results this morning.
Analyst Vijay Kumar commented, "MDT started 2017 with a solid execution, highlighted by all around revenue beat and operating margins that were generally in line with ST (came in above us). The importance of this Q cannot be underestimated in our mind, as sentiment had turned negative (post a disappointing 1H) and the stock... More
Medtronic (MDT) Tops Q3 EPS by 1c; Reiterates Outlook
February 21, 2017 6:50 AM ESTMedtronic (NYSE: MDT) reported Q3 EPS of $1.12, $0.01 better than the analyst estimate of $1.11. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.23 billion.
GUIDANCE:
Medtronic sees FY2017 EPS of $4.55-$4.60, versus the consensus of $4.56.
Outlook and Guidance
The company today reiterated its fiscal year 2017 revenue outlook, EPS guidance, and free cash flow outlook.
The company continues to expect fiscal year 2017 revenue growth to be within the mid-single digit... More
